Introduction
Inborn errors of metabolism are collectively common, affecting approximately one in every 500 newborns. 1 Disease phenotypes are frequently severe, and in many instances, inadequately managed by current therapies. These include dietary, drug, enzyme replacement and cellular therapies, encompassing bone marrow and liver transplantation. [2] [3] [4] Modes of presentation range from acute metabolic decompensation in the newborn period, through late onset acute and recurrent symptoms, to chronic progressive generalized or organ-specific dysfunction. 5 The underlying cause is invariably the functional deficiency of a specific enzyme, enzyme subunit or transport protein associated with a metabolic pathway. Close to 10% of currently annotated human genes encode enzymes or enzyme subunits, 6 explaining the prevalence and clinical importance of metabolic disease. Inheritance is predominantly, but not exclusively, recessive.
While many metabolic diseases involve multiple tissues, a substantial number exhibit organ-or tissue-specific dysfunction improving the prospect for gene-based therapeutic intervention. The liver is a particularly important potential target reflecting the extent of metabolic processes performed. These include carbohydrate, lipid and protein intermediary metabolism, plasma protein biosynthesis, bile acid production and detoxification of potentially harmful metabolites and xenobiotics. 7 Other targets of major importance are skeletal and cardiac muscle, the central nervous system and the hematopoietic compartment.
Relevant aspects of vector performance and biology

Vector tropism for metabolically important target tissues
Preclinical studies in small animal models have shown AAV vectors to be capable of highly efficient and stable gene transfer to the liver, skeletal muscle and the heart. Indeed following systemic administration it has proven possible to transduce a very high proportion of hepatocytes, myofibers and cardiomyocytes in the mouse with vectors packaged into capsid serotypes 8, 6 and 9, respectively. [8] [9] [10] Highly efficient transduction of neurons has also been achieved in the brain following direct interstitial injection of AAV with several different capsid serotypes, albeit in focal regions. 11, 12 Similar high levels of transduction have not yet been duplicated in the same tissues of large animal models, and the optimal capsid serotype for targeting specific tissues may vary between species. 13 Most available capsid tropism data have been generated in mice.
Impact of proliferation in target cell populations
Episomal AAV vector genomes, the predominant form in transduced cells, are rapidly lost in actively dividing cell populations through both degradation and dilution. The observed stability of transgene expression in hepatocytes, myofibers, cardiomyocytes and neurons is therefore explained by low or absent mitotic activity in these cell populations. Similarly, high rates of proliferation in hematopoietic cell populations at least partly explain the poor results achieved in this compartment.
As the majority of metabolic diseases present early in life, the potential impact of liver growth and associated hepatocellular proliferation on AAV-mediated transduction requires special consideration. Studies in adult mice have shown that partial hepatectomy, which is associated with a burst of hepatocellular proliferation, leads to rapid loss of episomal vector genomes. [14] [15] [16] Essentially the same phenomenon is seen following vector delivery to neonatal mice, where high rates of hepatocellular proliferation result in almost complete clearance of episomal vector genomes within two doublings of liver mass occurring within the first 1-2 weeks of life. 17, 18 A stable basal level of transgene expression, probably reflecting vector integration, persists thereafter in up to 8% of hepatocytes depending on the vector dose used. In human infants the first doubling of liver mass takes considerably longer, 8-9 months, and the second doubling a further 3 years. 19 While vector loss associated with hepatocellular proliferation is therefore likely to be slower in human infants, a decline in transgene expression can nevertheless be anticipated. The therapeutic importance of this decline will depend on whether the residual level of stable transgene expression is sufficient to favorably modify the disease phenotype being treated.
Vector immunobiology
An attractive feature of AAV vectors is the capacity to sustain expression of transgenes encoding foreign proteins in immune competent animal models. This capacity has been attributed to inefficient transduction of dendritic cells and minimal activation of innate immunity, which are pivotal in initiating immune responses. 20, 21 Depending on the context, however, immune evasion is incomplete with responses documented against both vector capsid proteins and encoded transgene products. Variables include route of delivery, vector dose, capsid pseudo-serotype, target organ, target species and compartmentalization of the transgene product. 22, 23 Natural infection with wild-type virus stimulates anti-capsid responses, detectable as serum antibodies, and preexisting immunity can impair transduction. 22 Cell-mediated responses against vector capsid have also been detected in human clinical trial subjects and healthy individuals. 24 In the context of human trials, targeting liver and muscle, respectively, these anti-capsid responses have been linked by some investigators to observed declines in factor IX and lipoprotein lipase from potentially therapeutic levels. 25, 26 Equivalent cell-mediated effects have proven difficult to replicate in small animal models, and the nature of immune mechanisms involved remains a subject of debate. 23, 27 Understanding host-vector immune interactions and immunobiology of specific target organs, such as the liver, skeletal muscle and brain, will be particularly critical to the successful deployment of AAV vectors in the treatment of metabolic disease. The liver, for example, is recognized to have tolerogenic properties. 28 In small animal models liver-targeted AAV-mediated gene delivery has been associated with induction of tolerance toward encoded transgene products, 29 and more recently similar observations have been made in skeletal muscle, a relatively more immunogenic tissue, albeit only at higher levels of transgene expression. 30 Vector delivery to the brain results in either nonresponsiveness or immunity with vector location relative to the blood-brain barrier influencing the response. 31 Collectively these observations suggest that with increased knowledge it is likely to be possible to develop rAAV delivery strategies that favor immune nonresponsiveness and or tolerance to transgene products.
Vector safety
The helper dependence, low immunogenicity and lack of overt pathogenicity of wild-type AAV provide a favorable biological basis for AAV vector safety. Additionally, the theoretical risk of insertional mutagenesis is reduced, as the majority of transduction events following AAV-mediated gene transfer result from the formation of transcriptionally active episomes rather than vector integration.
14,32 Recent reports, however, linking tumor formation in the mouse liver to integration events are currently causing a reevaluation of theoretical assumptions. 33, 34 Whether integration events are truly causative of observed tumors remains controversial as the observation of tumor formation is inconsistent across multiple studies. 35, 36 This may be partially explained by a higher risk of tumor formation in mice treated as neonates and the need for long-term follow-up because of protracted tumor latency. This controversy requires resolution and should be carefully considered in risk-benefit analysis before undertaking further liver-targeted human studies, particularly in diseases where contemporary therapies are adequate.
Correction of metabolic disease in animal models
To date gene therapy approaches to the treatment of approximately 30 different metabolic disease phenotypes have been undertaken in animal models using AAV vectors. In a significant number of instances the disease phenotype has either been corrected or substantially ameliorated, underscoring the exciting potential of AAV vectors for metabolic disease.
Lysosomal storage diseases
Lysosomes are membrane-bound organelles containing a diverse set of acidic hydrolases required for the degradation and recycling of cellular macromolecules. Deficiency in the function of lysosomal enzymes leads to the accumulation (storage) of incompletely metabolized substrate with resultant progressive cellular, tissue and organ dysfunction. Lysosomal storage diseases (LSD) include the mucopolysaccharidoses (MPS), oligosaccharidoses, sphingolipidoses, mucolipidoses, lipid storage AAV vectors in the treatment of metabolic disease IE Alexander et al diseases, neuronal ceroid lipofuscinoses, glycogen storage disease (GSD) type II and lysosomal transport defects. Disease phenotypes vary depending on the specific enzyme defect and level of residual activity. Organomegaly and mental retardation are common but not invariable manifestations. Clinical management remains challenging with enzyme replacement therapy (ERT), bone marrow transplantation (BMT) and substrate depletion therapy offering therapeutic benefit in some instances. The first two modalities exploit the capacity of a number of lysosomal enzymes to trans-complement functionally deficient cells by enzyme uptake, whereas the third blocks synthesis of the potentially damaging disease-specific substrate. ERT has established therapeutic benefit for MPS I, MPS II, MPS VI, Gaucher and Fabry diseases and GSD II (Pompe disease). 37 A major shortcoming, however, of ERT is an inability to prevent central nervous system (CNS) pathology in conditions such as MPS I and MPS II as access of systemically administered enzyme to the CNS is limited by the blood-brain barrier. 37, 38 BMT, which has recognized efficacy in MPS I, infantile Krabbe disease, X-linked adrenoleukodystrophy and metachomatic leukodystrophy, circumvents limitations imposed by the blood-brain barrier on enzyme transfer by providing a pool of donor-derived myeloid cells that enter the CNS and become microglia that are capable of cross-complementing enzyme deficiency in host cells. 3, 39 The challenge therefore, in further advancing the currently limited treatment options for LSDs, is to both broaden the number of phenotypes amenable to therapy and to better treat CNS manifestations when present. The exciting potential of AAV-mediated gene delivery to meet this challenge is substantiated by data generated in over 40 studies in animal models involving at least 15 different LSD phenotypes. The most extensively investigated phenotypes are GSD II [40] [41] [42] [43] [44] [45] [46] and MPS VII [47] [48] [49] [50] [51] [52] [53] [54] and distillation of data obtained for these conditions provides representative insights across the spectrum of LSDs.
The infantile onset form of GSD II (Pompe disease) is characterized by cardiomegaly, macroglossia and progressive muscle weakness leading to cardiorespiratory failure and death within the first year of life. The condition is caused by the deficiency of acid a-glucosidase (GAA; acid maltase) leading to glycogen accumulation and muscle dysfunction. Successful treatment, irrespective of the modality used, will require sustained correction of enzyme levels in cardiac and skeletal muscle. Studies in GAA-deficient mice show that this is potentially achievable by either muscle transduction 40, 41 or by targeting transduction to a depot organ, such as the liver, 42 from which enzyme can be released into the circulation for uptake by other enzyme-deficient tissues. Depending on promoter selection and capsid pseudo-serotype used, clinically significant phenotype correction has been achieved with both strategies.
For most LSDs, however, the presence of systemic and CNS pathology makes successful treatment by gene therapy even more challenging. This is illustrated by studies in mice with MPS VII (Sly syndrome), a condition caused by deficiency of b-glucuronidase (GUSB). Common features in affected individuals include coarse facies, hepatosplenomegaly, skeletal abnormalities, umbilical and inguinal hernias, visual and auditory dysfunction and mental retardation. Initial studies of phenotype correction in the mouse using AAV vectors, performed in the late 1990s, focused on systemic delivery of enzyme by either direct intramuscular or intravenous injection. 47, 48 While intramuscular injection resulted in high localized enzyme production, cross-correction of other tissues was limited, probably as a consequence of inadequate local secretion and distal tissue uptake. Intravenous delivery resulted in measurable enzyme levels in a number of tissues, most notably the liver in which glycosaminoglycan levels were normalized with an associated dramatic drop in storage granules. Other and more recent studies have focused on CNS and ocular manifestations [49] [50] [51] 53, 54 and systemic delivery has not yet been revisited with newer capsid serotypes. It is highly likely that studies with muscle and liver tropic capsids, such as 6 and 8 in the mouse, respectively, would give more robust systemic correction, although strategies to improve the cross-complementation properties of GUSB may also be required. 52 Studies in the CNS have included direct stereotactic delivery, and intraventricular and intrathecal injection. 49, 50, 52, 54 Durable correction of characteristic CNS pathology has been achieved following direct injection, albeit localized around the injection site. The most impressive results have been achieved following intraventricular delivery using a serotype 1 capsid in neonatal mice. While transduction was limited to defined regions, enzyme was detected throughout all regions of the brain with complete reversal of neuropathology for at least 1 year. 54 Collectively these data and results obtained in other LSDs give cause for optimism regarding the prospects of successful human therapy. Combinatorial approaches, involving different vector pseudo-serotypes and routes of delivery, will almost certainly be required to cover both systemic and CNS pathology. Alternatively, AAVmediated gene delivery might be used as an adjunct to ERT, with the CNS being a particularly important target. Identifying optimal capsid serotypes for use in the human brain and achieving widespread transduction, or enzyme uptake, remain fundamental challenges.
Disorders of amino acid and protein metabolism
This group of conditions encompasses disorders of ammonia detoxification, amino acid and peptide metabolism, and classical and cerebral organic acidurias. Specific examples that have been investigated as therapeutic targets using rAAV include ornithine transcarbamylase (OTC) deficiency, 55 phenylketonuria (PKU) [56] [57] [58] [59] homocytinuria, 60 methylmalonic aciduria (MMA) 61 and Canavan disease, 62,63 a cerebral organic aciduria. OTC deficiency provides an ideal paradigm for an inborn error of hepatocyte metabolism potentially amenable to gene therapy. 64 The condition is X-linked, although heterozygous females are sometimes symptomatic. 65 In its most severe form the condition presents in the newborn period with hyperammonemia and, if left untreated, progresses rapidly to coma and death. Aggressive medical therapy has the potential to hold ammonia levels in check until the infant is old enough to undergo liver transplantation, usually in the second half of the first year of life. Up to this time, however, intercurrent viral illnesses and other metabolic stresses, such as fasting, can induce spikes in blood ammonia to neurotoxic levels with resultant cumulative intellectual disability. Such infants commonly have little or no AAV vectors in the treatment of metabolic disease IE Alexander et al residual enzyme activity. Patients with as little as 3% residual enzyme activity have a milder phenotype more readily managed by conventional therapy. 66, 67 Two mouse models of OTC deficiency exist, spf and spf ash mice, each with less than 10% wild-type enzyme activity. While not hyperammonemic these mice have excessive levels of orotic acid in their urine, a surrogate marker of OTC deficiency that allows longitudinal analysis of disease correction in individual mice. Relatively robust phenotype correction has been reported for both mouse strains following portal vein injection of adult mice, with AAV capsid serotypes 7, 8 and 9. 55 While high vector doses were used with resultant enzyme levels up to approximately 50% wild type, minimum effective levels of gene transfer required for therapeutically useful phenotype amelioration have yet to be established.
PKU is one of the most commonly encountered metabolic phenotypes with many tertiary referral centers caring for large cohorts of patients. Diagnosis is commonly made through newborn screening, and early dietary intervention offers an excellent prognosis. The condition is caused by deficiency of the liver enzyme phenylalanine hydroxylase. Elevated blood phenylalanine levels and tyrosine deficiency underlie the neuropathology that develops in the absence of adequate dietary therapy. Similar to results achieved for OTC deficiency, relatively robust phenotype correction has been achieved in mice, albeit more effective and durable in males, possibly as a consequence of higher initial levels of transduction. [56] [57] [58] [59] The weakness of PKU as a target for gene therapy is the availability of effective dietary therapy.
The remaining conditions in this class investigated to date, homocystinuria, MMA and Canavan disease, are more formidable prospects. Homocystinuria, caused by cystathionine b-synthase (CBS) deficiency, is characterized by multisystem dysfunction, including developmental delay, skeletal abnormalities, ectopia lentis and a predisposition toward thrombosis. Approximately 50% of patients are completely or partially pyridoxine responsive, with the remainder dependent on a combination of dietary and pharmacological therapy. Adequate control of elevated blood homocysteine levels is associated with improved neurological outcomes and a reduced thrombotic tendency, but may be insufficient to prevent other manifestations even when initiated in the newborn period. This caveat aside, liver transplantation has recently been shown to control blood homocysteine levels in the absence of dietary measures. 68 Reported reduction in plasma homocysteine levels after systemic AAV-mediated gene delivery is therefore likely to be the consequence of liver transduction. Whether more widespread transduction will be required for complete phenotype reversal, reflecting the natural pattern of CBS expression across multiple tissues, is unknown.
Classical MMA is caused by deficiency of methylmalonyl-coenzyme A (CoA) mutase (MUT), a vitamin B 12 -dependent mitochondrial enzyme. Functional deficiency can therefore also be caused by defects in B 12 (cobalamin) absorption, metabolism or transport. In addition to the risk of acute metabolic decompensation, complications include mental retardation, extrapyramidal movement disorders, osteoporosis and progressive renal failure. Medical management is extremely challenging and the role of liver and liver-kidney transplantation remains controversial because of the systemic nature of the enzyme defect. While metabolic control is more readily achieved following liver transplantation, ongoing metabolic damage to the kidneys and brain has been reported. 69, 70 This may be explained by substantial production of methylmalonic acid by other tissues, such as skeletal muscle. 71 To date AAV2/2 and AAV2/8 vectors encoding cob(I)alamin adenosyltransferase have been produced and functionally validated in healthy mice following portal vein delivery. This enzyme is involved in conversion of cobalamin to adenosylcobalamin, a coenzyme for methylmalonyl-CoA MUT. While AAV2/8 vectors were more efficient, both vectors were capable of producing physiological levels of enzyme activity. 61 Therapeutic efficacy in mice with methylmalonic acidemia has yet to be established, although studies with adenoviral vectors confirm that liver-directed gene delivery favorably modifies phenotype, extending survival in a neonatal lethal model. 72 Canavan disease is caused by deficiency of aspartoacylase resulting in accumulation of N-acetylaspartic acid (NAA) in the brain. Affected infants and children exhibit progressive psychomotor retardation, epileptic encephalopathy, macrocephaly and leukodystrophy. There is no effective treatment. Mouse and rat models exist and both have been used to investigate AAV-mediated gene delivery. 62, 63 Following stereotactic injection regional improvements in characteristic neuropathology have been achieved in concert with reduced NAA levels as assessed by MRS. In rats, improved balance and coordinated locomotion was also observed. 63 
Disorders of energy metabolism
Defects in energy metabolism encompass disorders of mitochondrial function, fatty acid oxidation, ketogenesis, ketolysis and creatine biosynthesis. While mitochondria play an important role in fatty acid oxidation, the term mitochondrial disease is usually reserved for defects in enzymes or enzyme complexes directly involved in the production of chemical energy through oxidative phosphorylation. While all cells and tissues are dependent on mitochondrial function, defects in energy metabolism commonly manifest clinically in tissues and organs with high energy demand, most notably in muscle, the CNS and liver. Clinical involvement of multiple organ systems is therefore easily understood, but organ-specific phenotypes are also well described. Examples of the later scenario have been considered as targets for AAVmediated gene therapy. These include defects in the pyruvate dehydrogenase complex (PDHC), Leber's hereditary optic neuropathy (LHON) and adenine nucleotide translocator (ATN1) deficiency. [73] [74] [75] [76] Deficiency of the PDHC in most cases presents as a neurodegenerative disorder of variable severity. Facial dysmorphism and structural abnormalities of the brain are also described. The condition is most commonly caused by deficiency of the X chromosome-encoded E1a subunit of the PDHC. Interestingly, both males and females are affected, consistent with an X-linked dominant mode of inheritance. The disease mechanism in females is thought to involve X chromosome inactivation, which would not preclude gene addition strategies as a mode of therapy. Vectors encoding the E1a subunit have been AAV vectors in the treatment of metabolic disease IE Alexander et al constructed and tested in vitro and in vivo, but to date only partial restoration of PDHC activity has been achieved in cultured patient fibroblasts. 73, 74 LHON is a maternally inherited form of blindness that usually develops in early adulthood with a gender bias toward males. The disease is caused by homoplasmic mutations in the mitochondrial genome that lead to retinal ganglion cell degeneration and apoptotic death. The underlying molecular mechanisms remain incompletely understood but in many cases involve functional complex I deficiency with resultant defects in respiratory chain function and possibly the generation of reactive oxygen species (ROS). The disease phenotype has been successfully mimicked in mice by intraocular AAVmediated delivery of hammerhead ribozymes directed against mitochondrial superoxide dismutase (SOD2), a result supportive of the role of ROS in disease pathophysiology. 75 Related studies in LHON cells involving AAV-mediated delivery of SOD2 have also shown protection against antioxidant stress. 77 Whether this approach would ameliorate phenotype in vivo remains to be tested and more direct approaches involving delivery of deficient gene products encoded by the mitochondrial genome (mtDNA) have not been reported. This raises the generic challenge of treating mitochondriopathies caused by mutations in mitochondrial genes, as the hydrophobicity of mtDNA-encoded proteins has been reported to impair import from the cytoplasm. 78 
Disorders of lipoprotein metabolism
Lipoproteins constitute the lipid transport system of the blood. Inborn errors include the hypercholesterolemias, hyperlipidemias, hypertriglyceridemias, disorders of high-density lipoprotein metabolism and disorders with deceased low-density lipoprotein (LDL), cholesterol and triglycerides. To date, two conditions in this class have been investigated in animal models as targets for AAV-mediated gene therapy, familial hypercholesterolemia, due to mutations in the LDL receptor 79, 80 and lipoprotein lipase deficiency. 81, 82 Liver-targeted gene transfer of the human LDL receptor resulted in close to complete normalization of serum lipid levels and prevention of severe atherosclerosis in LDL receptor deficient mice when using AAV vectors with serotype 7 and 8 capsids. 79 The type 2 capsid performed markedly less well with only partial phenotype correction. Similarly, lipoprotein lipase deficiency has been successfully treated in both mouse and cat models with clearance of visible hyperlipidemia and plasma triglycerides reduced to near normal levels by muscle-directed delivery using a vector with a serotype 1 capsid. 81, 82 Long-term follow-up in mice showed correction lasted at least 1 year. 81 
Disorders of carbohydrate metabolism
Inborn errors include disorders of glucose, galactose, fructose, glycerol and pentose metabolism. Disorders of glucose metabolism encompass the GSDs, defects in gluconeogenesis and glucose transport and congenital hyperinsulinism. A substantial proportion of these conditions can be managed with a combination of dietary and pharmacological therapy, but there remains a number where existing therapies are inadequate. Excluding GSD II, which is discussed as an LSD, GDS Ia is the only disease in the class to have received attention as a possible target for AAV-mediated gene therapy. [83] [84] [85] While dietary therapy has improved growth and survival, improved therapies are required to address problematic long-term complications, including liver tumors, osteoporosis and renal failure. The possibility of ERT, as described for GSD II, is precluded by the fact that the deficient enzyme, glucose-6-phosphatase-a, is a hydrophobic endoplasmic reticulum-associated transmembrane protein that cannot be expressed in a soluble active form. 86 Murine and canine models of GSD Ia exist, and both have been used to explore AAV-mediated phenotype correction. [83] [84] [85] In mice, substantial biochemical correction, including abnormal glycogen storage, has been achieved with vectors bearing serotype 1 or 8 capsids., 84, 85 In dogs, consistent reduction in liver glycogen has been achieved with normalization of fasting glucose, cholesterol, triglycerides and lactic acid reported in one animal. Whether longer term complications mentioned earlier can be ameliorated remains unknown, and truly effective therapy is likely to require highly efficient gene delivery to both liver and kidney.
Other metabolic disorders
Other metabolic conditions, not elsewhere classified, that have been investigated in animal models using AAV-mediated gene transfer include a-1-antitrypsin deficiency [87] [88] [89] molybdenum cofactor deficiency 90 and Crigler-Najjar syndrome, caused by deficiency of bilirubin UDP glucuronosyltransferase. 91 In this latter condition, Gunn rats were studied comparing vectors bearing the serotype 1, 2, 6 and 8 capsids. After intraportal injection all treatment groups showed reduced serum bilirubin levels, with the serotype 1 and 8 capsids being most effective. Interestingly, antibodies directed against the transgene product were observed for all capsids. Substitution of the cytomegalovirus promoter with a liver-specific albumin promoter, and delivery with a serotype 1 capsid, ameliorated this effect suggesting extrahepatic transgene expression was required for antibody induction. Similarly, liver-targeted delivery of MOCS1 to double knockout mice using an AAV-1/2 chimeric capsid proved effective in rescuing the neonatal lethal phenotype of molybdenum cofactor deficiency and also prevented death and disease progression in mice maintained into adulthood using biochemical substitution therapy. 90 Finally, therapeutic serum a-1-antitrypsin levels, potentially sufficient to prevent the development of emphysema, have been achieved in mice following either intramuscular 87 or intrapleural delivery. 88, 89 For intrapleural delivery, the rhesus AAVrh.10 capsid was most effective and may circumvent preexisting anti-capsid immunity in human trials. The intramuscular route of delivery, using the serotype 2 capsid has already been investigated in humans as described below.
Challenges of human therapy
Given the increasing number of publications reporting the successful treatment of small animal models of disease by gene therapy, there is a need to focus greater effort on surmounting the challenges inherent in translating success at the laboratory bench to successful human therapy. These challenges are biological, ethical and logistic. Biological challenges include interspecies AAV vectors in the treatment of metabolic disease IE Alexander et al differences in disease biology, vector performance, hostvector interactions and increased size with the associated necessity to functionally correct a greater number of cells to reach the threshold required for therapeutic benefit. Depending on the specific disease phenotype being addressed, some of these challenges may be surmounted in preclinical studies using humanized mouse models and large animal models when available. Others can only be addressed by cautiously moving to human clinical trials where results are used in an iterative manner to inform ongoing laboratory research and subsequent human trials.
Ethical and logistic challenges are equally daunting. First, the choice of target disease must be ethically defensible based on careful analysis of potential risks and benefits to trial participants. Severe phenotypes, where existing treatments are inadequate or high risk and the prognosis poor or guarded, are most readily justified. Second, most metabolic diseases with severe phenotypes present in infancy and early childhood. This raises questions about whether first-in-man trials should be restricted to adults and whether parents can ever give informed consent or are 'coerced by the disease of their child'. 92 Major ethical debate along these lines was evident in the Jesse Gelsinger case, with arguments against enrolling infants prevailing despite the fact that the severe form of OTC deficiency only occurs in this group. The biological reality is that infants and children are not small adults and their involvement in clinical trials is indispensable to the development of improved therapies for pediatric metabolic and other diseases. This need to involve children, combined with the relative rarity of ethically defensible disease phenotypes for first-in-man studies presents a challenge to the classical progression from phase I safety trials. For pediatric participants it can reasonably be argued that while safety might be the primary aim of a study, there should always be a realistic possibility of therapeutic benefit.
Finally, meeting the toxicological, manufacturing and regulatory requirements of human clinical trials is inherently demanding. These are not only expensive and time consuming, taking up to 2 years, but also attract little or no academic credit, and covering the costs involved is particularly difficult for orphan diseases, many of which are metabolic.
Clinical trials for metabolic disease
Up to the present time approximately 50 human clinical trials using rAAV-mediated gene transfer have been approved 93 with about 10% targeting metabolic disease phenotypes. These include Canavan disease, 94 a-1-antitrypsin deficiency, 95 late infantile neuronal ceroid lipofuscinosis 96 and lipoprotein lipase deficiency. 97 All are phase I or I/II. Two of these conditions, Canavan disease and late infantile neuronal ceroid lipofuscinosis, involve targeting of the central nervous system and necessitate the enrolment of children. For the remaining two conditions, a-1-antitrypsin deficiency and lipoprotein lipase deficiency, the approach employed involved targeting gene delivery to skeletal muscle. In both instances the aim was to create a depot for systemic enzyme release.
For two of these studies early results have been published. In the phase I Canavan disease and a-1-antitrypsin deficiency trials 10 children and 12 adults, respectively, have been treated. 98 In both trials anti-capsid (serotype 2) antibody response were detected, although only in a minority of subjects in the Canavan disease trial, consistent with the relatively immuno-privileged nature of the CNS. No adverse events were observed in either trial. In the lipoprotein lipase deficiency phase I/II trial, preliminary data from eight patients has been published in abstract form. 26, 99 Excitingly, early evidence of efficacy has been observed with a trend toward reduced triglyceride levels. While no adverse events were observed, one subject in the higher vector dose cohort, who initially responded to therapy, had a transient rise in creatine phosphokinase levels that correlated with loss of therapeutic efficacy. Evidence was consistent with this effect being mediated by an anticapsid (serotype 1) cell-mediated immune response reminiscent of that reported in a human hemophilia trial after liver-directed AAV vector delivery with a serotype 2 capsid. 24, 25 Collectively, these early human trial data point to a need to thoroughly understand AAV vector immunobiology in the human context and have lead some to propose transient immunosuppression at the time of initial vector exposure in future human studies.
Conclusion
While much remains to be achieved in preclinical studies, the successful correction of multiple metabolic phenotypes in small animal models using AAV-mediated gene transfer demands that increasing emphasis be placed on addressing the challenges of successful translation to human therapy. The rapidity of progress in both vector development and our understanding of disease pathophysiology give cause for considerable confidence that these challenges can be overcome. The key will be the careful selection of target disease phenotypes, taking into account biological, ethical and logistic issues, combined with an iterative approach to integrating preclinical and clinical research.
